Immunohistochemistry Market: Growth, Size, Share, and Trends

Report Code BT 4780
Published in Aug, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Immunohistochemistry Market by Product (Antibodies (Type, Clonality), Reagents, Equipment, Kits, Software), Application (Diagnostics (Cancer, Infectious, Autoimmune, Neurological), Research (Drug Development), Forensic) - Global Forecast to 2029

Overview

The global immunohistochemistry market growth forecasted to transform from $3.7 billion in 2024 to $5.2 billion by 2029, driven by a CAGR of 7.2%. The increasing number of cancer cases is one of the key factors driving the uptake of IHC products, which, in turn, leads to a greater need for accurate and efficient diagnostic tools such as IHC tests. Additionally, market players have increasingly focused on innovation, including developing new antibodies and manufacturing automated equipment, which enhances the accuracy and efficiency of cancer detection and treatment. Moreover, the adoption of personalized treatment plans is also rising, making it a significant opportunity for market players. However, in situ hybridization, NGS, and RNA sequencing are a few of the alternative technologies challenging the market growth of IHC products, which can limit market growth to some extent.

Attractive Opportunities in the Immunohistochemistry Market

Asia Pacific

The The market growth in the Asia Pacific can be attributed to the presence of a larger patient population, increasing incidence of chronic diseases, increasing demand for quality medical facilities (including diagnostics and therapy), and an increase in healthcare expenditure and government initiatives in this region.

The growth of this market can be attributed to the growing incidence of cancer leading to a growing need for its diagnostics, and an availability of reimbursement coverage for IHC tests.

Globally, North America is the largest market for Immunohistochemistry market and this trend is expected to continue during the forecast period

The increasing demand for companion diagnostic and personalized medicine are viewed as significant opportunity areas for the growth of IHC market during the forecast period.

The Asia Pacific market is estimated to witness the highest CAGR during the forecast period.

Global Immunohistochemistry Market Dynamics

Driver: Adoption of Digital Pathology

Digital pathology uses digital aids to capture images of IHC slides and store and use them for analysis; this helps in observation and interpretation, which results in diagnosis. Digital slides are digital images captured using a slide scanner; these can be remotely analyzed and interpreted by pathologists. Additionally, new algorithms are being developed to automate and speed up the analysis of digital slides. The significant advantages offered are reduced turnaround time, increased archive availability for future reference without the need to maintain physical slides, improvised workflow, and increased focus of pathologists on specialized requirements. The major players offering digital IHC are F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems (Danaher Corporation) (Germany), and Agilent Technologies, Inc. (US).Governments and industry players globally have focused on various strategies in the field of digital pathology to provide a highly advanced, fast, and accurate diagnosis. Some key developments in this regard have been listed below:In June 2024, F. Hoffman La-Roche received 510(k) clearance from the US FDA for the Digital Pathology Dx (VENTANA DP 200) solution. The system helps review and interpret the digital images of scanned pathology slides for disease diagnosis.In January 2023, Agilent Technologies, Inc. entered into a strategic partnership with Akoya Biosciences, Inc. to develop end-to-end multiplex IHC diagnostic solutions and commercialized workflow solutions for multiplex assays aiding in biomarker clinical research utilizing digital pathology.In June 2022, Roche launched its digital pathology slide scanner system—VENTANA DP 600—to develop digital images of stained tissue samples.

Restraint: Adoption of Alternative Technologies

IHC is a laboratory technique that utilizes antibodies to identify disease-specific antigens (markers) in tissue samples employed in diagnostic and research applications. However, the availability of alternative technologies such as FISH, RNA Sequencing, and NGS for diagnostic and research purposes restrain the growth of the IHC market to a certain extent.FISH is a cytogenetic technique that helps identify and visualize specific DNA sequences or chromosomal abnormalities within cells. This method also provides valuable data on DNA amplification at a genetic level for which IHC tests are inconclusive, as while IHC tests help detect protein expression, a direct measurement of gene copy number or gene amplification is not possible with these tests. This technique helps diagnose genetic diseases, map genes, and identify genetic abnormalities, particularly in cancer diagnoses, where IHC alone may be insufficient.RNA sequencing, or transcriptome sequencing, is another alternative method to IHC. This method is used to determine the presence and quantity of RNA molecules within a cell, allowing the assessment of gene expression profiles.Next Generation Sequencing (NGS) is a parallel sequencing technology that enables high-throughput sequencing of DNA, aiding in a detailed analysis of the genetic composition (nucleotide order) and expression patterns in tissue samples. The technology combined with RNA sequencing methods is used to discover novel RNA variants and splice sites or quantify mRNAs for gene expression analysis. NGS is used for molecular profiling and identifying genetic alterations in tissue samples; it is an alternative to IHC for diagnosing and researching complex genetic conditions.Thus, the available alternative techniques are expected to restrain the growth of the IHC market to a certain extent.

 

Opportunity: Growing adoption of companion diagnostics

Companion diagnostics is a test that matches a patient with appropriate therapy using a personalized approach. This test helps identify specific genes or biomarkers for a disease targeted by an associated drug in patients. The co-development of companion diagnostics with therapeutic products can significantly alter the drug development process and commercialize drug candidates by developing safer drugs with enhanced therapeutic efficacy faster and more cost-effectively. The increasing demand for high-priced specialist therapies and safer drugs has led to the growth of the companion diagnostics market. The growing importance of companion diagnostics has also provided growth opportunities for the diagnostics segment and, in turn, the IHC market.In October 2022, Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody received approval from the US FDA; this is the first IHC-based companion diagnostic used to identify metastatic breast cancer patients with low HER2 expression for whom Enhertu (fam-trastuzumab deruxtecan-nxki) can be a viable treatment option. Also, there has been an increasing number of collaborations among diagnostic and pharmaceutical companies for IHC companion diagnostics for improved diagnosis and personalized therapeutic approaches. For instance, in January 2023, AstraZeneca partnered with Thermo Fisher to develop Solid Tissue and Blood-Based companion diagnostic tests for Tagrissio. Such developments support the drug development and approval processes, improve patient outcomes, encourage research collaborations, and drive the growth of the IHC market.

Challenge: Lack of standardization

The IHC technique is mainly used as a diagnostic method and for some research applications. There is a growing demand for IHC products for the diagnosis of chronic indications, especially cancer, due to the increasing adoption of targeted or personalized approaches to cancer therapeutics and an ever-growing incidence of the disease. This increase in cancer incidence has led to a rising need to standardize diagnostic procedures and the products used in these procedures. Standardization in IHC helps achieve consistent, reliable, and reproducible results across laboratories and improves inter-laboratory comparability and clinical utility. It helps compare research, enhance quality control, and ensure regulatory compliance. However, there is an observed lack of standardization in IHC. For instance, IHC equipment used for diagnostic applications requires particular consumables for particular equipment, which need to be bought from specific vendors only. Thus, a lack of standardization restricts the use of any consumable available and could result in less cost-effectiveness or inconvenience for the end user. However, the growing demand for IHC products for diagnostic and research applications is encouraging the market players to standardize their offerings and make them more standardized; this is expected to lower the effect of this challenge.

Global Immunohistochemistry Market Ecosystem Analysis

Immunohistochemistry: Market Ecosystem The ecosystem of the IHC market includes product providers and end users such as hospitals and diagnostic laboratories, academic & research institutes and contract research organizations, and other end users such as pharmaceutical & biotechnology companies and forensic laboratories. The product suppliers develop, manufacture, and distribute IHC products such as antibodies, reagents, kits, and instruments for diagnosis and research. The market ecosystem for IHC is a complex and dynamic network of players, all working together to advance diagnosis, treatment, and research for various diseases. The key players in the IHC market are F. Hoffmann-La-Roche Ltd. (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories Inc. (US), Bio-Techne (US), Thermo Fisher Scientific Inc. (US), and PHC Holdings Corporation (Japan), among others.

 

Based on application, the diagnostic applications segment accounted for the largest market share of the immunohistochemistry industry.

Based on application, the immunohistochemistry market is segmented into diagnostic, research, and forensic applications.The diagnostic applications segment held the largest market share of the IHC market in 2023 and is projected to register the highest growth rate during the forecast period. Factors such as an increasing incidence of chronic diseases, such as cancer, autoimmune conditions, and neurological disorders, drive the demand for IHC tests for disease diagnosis. IHC tests enable pathologists to differentiate two disease processes by determining the presence or absence of specific proteins, aiding in reliable decision-making; these advantages offered by IHC methods support market growth.

Antibodies accounted for the largest share of the immunohistochemistry industry based on products.

The immunohistochemistry market is segmented into antibodies, reagents, equipment, and kits based on product. In 2023, the antibodies segment accounted for the largest share of the IHC market; this large share can be attributed to the availability of a wide range of catalogs and custom antibodies. Players operating in the IHC market have also focused on innovation and launched novel antibodies offering higher sensitivity, specificity, and accurate outcomes. Moreover, the significance of primary and secondary antibodies in diagnostic applications is also expected to support the segment growth.

North America Region Holds the Largest Share of the Immunohistochemistry Market.

The global immunohistochemistry market is broadly segmented into six major regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America reported the second-highest growth rate and accounted for the largest market size. The key factors supporting the market in the region are the presence of technologically advanced and well-established diagnostic lab infrastructure and a stronghold of the key players in the region. Additionally, the growing incidence of chronic and infectious diseases further supports the adoption of IHC products for diagnostic applications.

 
 

Recent Developments of Immunohistochemistry Market Industry

  • In April 2023, Leica Biosystems, a subsidiary of Danaher Corporation (US), received clearance from the US FDA for its BOND MMR Antibody Panel to detect colorectal cancer.
  • In January 2023, Agilent Technologies, Inc. (US) partnered with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays for IHC diagnostic applications.

Key Market Players

Want to explore hidden markets that can drive new revenue in Immunohistochemistry Market?

Scope of the Report

Report Attribute Details
Market Revenue in 2024 $3.7 billion
Projected Revenue by 2029 $5.2 billion
Revenue Rate Poised to Grow at a CAGR of 7.2%
Market Driver Adoption of Digital Pathology
Market Opportunity Growing adoption of companion diagnostics

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Immunohistochemistry Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
45
RESEARCH METHODOLOGY
50
EXECUTIVE SUMMARY
60
PREMIUM INSIGHTS
63
MARKET OVERVIEW
66
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing prevalence of cancer and rising geriatric population
    - Technological innovations and advancements in immunohistochemistry diagnostics
    - Favorable reimbursement coverage for immunohistochemistry tests
    - Growing focus on digital pathology
    RESTRAINTS
    - Adoption of alternative technologies in molecular diagnostics and research
    - Highly consolidated market
    OPPORTUNITIES
    - Growing demand for precision/personalized medicines
    - Increasing adoption of companion diagnostics
    - Growth opportunities in emerging economies
    - Integration of AI in immunohistochemistry
    CHALLENGES
    - Stringent regulatory requirements for tissue diagnostic instruments and consumables
    - Lack of standardization
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE OF IMMUNOHISTOCHEMISTRY PRODUCTS, 2023
    INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023
    INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021–2023
  • 5.5 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Automated immunohistochemistry systems
    - Multiplex immunohistochemistry
    COMPLEMENTARY TECHNOLOGIES
    - Chromogenic detection
    - Fluorescent detection
    ADJACENT TECHNOLOGIES
    - In situ hybridization
  • 5.6 PATENT ANALYSIS
    METHODOLOGY
    INNOVATION AND PATENT APPLICATIONS
    TOP PATENT APPLICANTS
  • 5.7 VALUE CHAIN ANALYSIS
    RESEARCH & DEVELOPMENT
    MANUFACTURING
    LOGISTICS AND POST-SALES
  • 5.8 SUPPLY CHAIN ANALYSIS
  • 5.9 ECOSYSTEM ANALYSIS
    ROLE OF RAW MATERIAL SUPPLIERS
    ROLE OF PRODUCT PROVIDERS
    ROLE OF END USERS
    ROLE OF REGULATORY AUTHORITIES
  • 5.10 PORTER’S FIVE FORCES ANALYSIS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.12 REGULATORY LANDSCAPE
    REGULATORY ANALYSIS
    - North America
    - Europe
    - Asia Pacific
    - Latin America
  • 5.13 KEY CONFERENCES AND EVENTS, 2024–2025
  • 5.14 INVESTMENT AND FUNDING SCENARIO
  • 5.15 IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET
IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING
110
  • 6.1 INTRODUCTION
  • 6.2 ANTIBODIES
    IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE
    PRIMARY ANTIBODIES
    - Increasing adoption of targeted immunotherapy to drive segment
    SECONDARY ANTIBODIES
    - Better signal amplification and easier manufacturing process to fuel segment growth
    IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY
    MONOCLONAL ANTIBODIES
    - Increased applications in cancer diagnostics to support market growth
    POLYCLONAL ANTIBODIES
    - Better sensitivity and higher resistant to changes in antigen conformation to augment segment growth
  • 6.3 REAGENTS
    HISTOLOGICAL STAINS
    - Growing focus on cancer diagnostics and developmental research to drive segment
    BLOCKING SERA AND REAGENTS
    - Need to prevent non-specific binding and provide accurate outcomes to drive adoption
    CHROMOGENIC SUBSTRATES
    - Rapid detection and faster diagnosis to propel segment growth
    FIXATION REAGENTS
    - Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption
    DILUENTS
    - Focus on reducing non-specific background staining during immunostaining to aid segment growth
    ORGANIC SOLVENTS
    - Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market
    PROTEOLYTIC ENZYMES
    - Proteolytic enzymes to improve accessibility of target antibodies
    OTHER REAGENTS
  • 6.4 EQUIPMENT
    SLIDE-STAINING SYSTEMS
    - Availability of technologically advanced slide-staining systems to fuel segment growth
    TISSUE PROCESSING SYSTEMS
    - High equipment cost and need for extensive regulatory compliance to limit market
    SLIDE SCANNERS
    - Accurate insights into complexity of tissue interactions and multi-parameter cellular expressions to aid adoption
    OTHER EQUIPMENT
  • 6.5 KITS
    HUMAN IMMUNOHISTOCHEMISTRY KITS
    - Increasing focus on cancer research to fuel segment growth
    ANIMAL IMMUNOHISTOCHEMISTRY KITS
    - Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth
  • 6.6 SOFTWARE
    GROWING FOCUS ON DIGITAL PATHOLOGY FOR MORE ACCURATE DIAGNOSIS TO DRIVE MARKET
IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION
179
  • 7.1 INTRODUCTION
  • 7.2 DIAGNOSTIC APPLICATIONS
    CANCER
    - Increasing target population and rising adoption of targeted therapies to propel market growth
    INFECTIOUS DISEASES
    - High prevalence of infectious diseases and need for early diagnosis to aid market growth
    NEPHROLOGICAL DISEASES
    - Rising prevalence of renal transplant-associated conditions to drive market
    AUTOIMMUNE DISEASES
    - Focus on differentiating autoimmune diseases from similar clinical presentations to augment market growth
    NEUROLOGICAL DISEASES
    - Increasing global burden of neurological disorders to spur market growth
    OTHER DISEASES
  • 7.3 RESEARCH APPLICATIONS
    DRUG DEVELOPMENT AND TESTING
    - Need for accurate and objective outcomes in drug testing to augment segment growth
    OTHER RESEARCH APPLICATIONS
  • 7.4 FORENSIC APPLICATIONS
    INCREASED DEMAND FOR EFFECTIVE DETERMINATION OF PATHOLOGICAL CHANGES TO SUPPORT MARKET GROWTH
IMMUNOHISTOCHEMISTRY MARKET, BY END USER
216
  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
    LOW COST OF SPECIALTY DIAGNOSTIC TESTS AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH
  • 8.3 ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS
    GROWING APPLICATION OF IMMUNOHISTOCHEMISTRY TESTS FOR DRUG DEVELOPMENT TO POSITIVELY IMPACT MARKET GROWTH
  • 8.4 OTHER END USERS
IMMUNOHISTOCHEMISTRY MARKET, BY REGION
228
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - US to dominate North American immunohistochemistry market during forecast period
    CANADA
    - High incidence of cancer and increased demand for advanced diagnostics to propel market growth
  • 9.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - High investments in life science R&D and favorable reimbursement policies to drive market
    UK
    - Rising prevalence of cancer and increasing government funding in health research to augment market growth
    FRANCE
    - Increased research in cancer diagnosis and treatment to support market growth
    ITALY
    - Advanced health infrastructure and high geriatric population to fuel market growth
    SPAIN
    - Increased demand for personalized medicines to boost adoption of immunohistochemistry products
    REST OF EUROPE
  • 9.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing focus on advanced cancer diagnostics to spur market growth
    JAPAN
    - High geriatric population and increased government healthcare expenditure to support market growth
    INDIA
    - Need for high-end pathology and diagnostic services to propel market growth
    AUSTRALIA
    - Increased patient population and high demand for quality healthcare to aid market growth
    SOUTH KOREA
    - Focus on precision healthcare and personalized medicines to drive market
    REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth
    MEXICO
    - Increasing research initiatives and rising cancer cases to drive market
    REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    - Saudi Arabia
    - UAE
    - Rest of GCC Countries
    REST OF MIDDLE EAST
  • 9.7 AFRICA
    RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
351
  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET
  • 10.3 REVENUE ANALYSIS, 2021–2023
  • 10.4 MARKET SHARE ANALYSIS, 2023
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Offering footprint
    - Application footprint
    - Region footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 10.7 COMPANY VALUATION AND FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 10.8 BRAND/PRODUCT COMPARISON
  • 10.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES AND APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
372
  • 11.1 KEY PLAYERS
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    - MnM view
    DANAHER CORPORATION
    - Business overview
    - Products/Solutions offered
    - Recent developments
    - MnM view
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    - MnM view
    PHC HOLDINGS CORPORATION
    - Business overview
    - Products/Solutions offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products/Solutions offered
    MERCK KGAA
    - Business overview
    - Products/Solutions offered
    BIO-RAD LABORATORIES, INC.
    - Business overview
    - Products/Solutions offered
    BIO-TECHNE
    - Business overview
    - Products/Solutions offered
    - Recent developments
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products/Solutions offered
    - Recent developments
    TAKARA BIO INC.
    - Business overview
    - Products/Solutions offered
    ENZO BIOCHEM INC.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    SINO BIOLOGICAL, INC.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    SAKURA FINETEK JAPAN CO., LTD.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    CELL SIGNALING TECHNOLOGY, INC.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    BIO SB
    - Business overview
    - Products/Solutions offered
    - Recent developments
    MILTENYI BIOTEC
    - Business overview
    - Products/Solutions offered
    ORIGENE TECHNOLOGIES, INC.
    - Business overview
    - Products/Solutions offered
  • 11.2 OTHER PLAYERS
    EAGLEBIO
    BIOCARE MEDICAL, LLC
    ELABSCIENCE BIONOVATION INC.
    BIOGENEX
    DIAGNOSTIC BIOSYSTEMS INC.
    HISTO-LINE LABORATORIES
    ROCKLAND IMMUNOCHEMICALS, INC.
    CANDOR BIOSCIENCE GMBH
    GENEMED BIOTECHNOLOGIES, INC.
APPENDIX
482
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMMUNOHISTOCHEMISTRY MARKET: IMPACT ANALYSIS
  • TABLE 3 ESTIMATED NUMBER OF NEW CASES, BY REGION, 2022–2045 (THOUSAND)
  • TABLE 4 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION, 2022–2050
  • TABLE 5 CPT CODES FOR IMMUNOHISTOCHEMISTRY PROCEDURES
  • TABLE 6 MAJOR ACQUISITIONS IN IMMUNOHISTOCHEMISTRY MARKET, 2020–2023
  • TABLE 7 AVERAGE SELLING PRICE FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2023
  • TABLE 8 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023 (USD)
  • TABLE 9 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021–2023 (USD)
  • TABLE 10 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
  • TABLE 11 TOP 20 PATENT OWNERS IN IMMUNOHISTOCHEMISTRY MARKET, 2014–2024
  • TABLE 12 INDICATIVE LIST OF PATENTS IN IMMUNOHISTOCHEMISTRY MARKET, 2022–2024
  • TABLE 13 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF RAW MATERIAL SUPPLIERS
  • TABLE 14 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF PRODUCT PROVIDERS
  • TABLE 15 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF END USERS
  • TABLE 16 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF REGULATORY AUTHORITIES
  • TABLE 17 IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 18 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY END USER
  • TABLE 19 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
  • TABLE 20 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
  • TABLE 21 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS
  • TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 24 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024–DECEMBER 2025
  • TABLE 25 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 26 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 27 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 28 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 34 PRIMARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 35 NORTH AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 EUROPE: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 LATIN AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 MIDDLE EAST: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 GCC COUNTRIES: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 SECONDARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 42 NORTH AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 EUROPE: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 LATIN AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 MIDDLE EAST: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 GCC COUNTRIES: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 49 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 50 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 57 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 64 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 HISTOLOGICAL STAINS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 72 NORTH AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 73 EUROPE: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 LATIN AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 MIDDLE EAST: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 GCC COUNTRIES: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 78 BLOCKING SERA AND REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 EUROPE: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 LATIN AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 MIDDLE EAST: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 84 GCC COUNTRIES: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 85 CHROMOGENIC SUBSTRATES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 EUROPE: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 90 MIDDLE EAST: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 91 GCC COUNTRIES: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 92 FIXATION REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 94 EUROPE: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 96 LATIN AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 97 MIDDLE EAST: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 98 GCC COUNTRIES: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 99 DILUENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 101 EUROPE: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 103 LATIN AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 104 MIDDLE EAST: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 105 GCC COUNTRIES: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 106 ORGANIC SOLVENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 107 NORTH AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 108 EUROPE: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 110 LATIN AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 111 MIDDLE EAST: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 112 GCC COUNTRIES: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 113 PROTEOLYTIC ENZYMES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 114 NORTH AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 115 EUROPE: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 117 LATIN AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 118 MIDDLE EAST: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 120 OTHER REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 121 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 122 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 124 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 125 MIDDLE EAST: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 126 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 128 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 129 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 130 EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 132 LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 133 MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 134 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 135 IMMUNOHISTOCHEMISTRY SLIDE-STAINING SYSTEMS MARKET, BY VOLUME, 2022–2029 (UNITS)
  • TABLE 136 SLIDE-STAINING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 137 NORTH AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 138 EUROPE: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 LATIN AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 141 MIDDLE EAST: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 142 GCC COUNTRIES: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 143 TISSUE PROCESSING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 144 NORTH AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 145 EUROPE: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 147 LATIN AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 148 MIDDLE EAST: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 149 GCC COUNTRIES: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 150 SLIDE SCANNERS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 151 NORTH AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 152 EUROPE: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 154 LATIN AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 155 MIDDLE EAST: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 156 GCC COUNTRIES: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 157 OTHER EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 158 NORTH AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 159 EUROPE: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 161 LATIN AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 162 MIDDLE EAST: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 163 GCC COUNTRIES: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 164 IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 165 IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 166 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 167 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 169 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 170 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 172 HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 173 NORTH AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 174 EUROPE: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 176 LATIN AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 177 MIDDLE EAST: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 178 GCC COUNTRIES: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 179 ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 180 NORTH AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 181 EUROPE: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 183 LATIN AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 184 MIDDLE EAST: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 186 IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 187 NORTH AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 188 EUROPE: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 190 LATIN AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 191 MIDDLE EAST: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 192 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 193 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 194 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 195 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 196 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 197 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 199 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 200 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 201 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 202 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
  • TABLE 203 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 204 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 205 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 207 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 208 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 209 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 210 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
  • TABLE 211 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 212 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 213 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 215 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 216 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 217 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 218 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 219 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 220 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 222 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 223 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 224 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 225 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 226 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 227 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 229 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 230 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 231 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 232 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR NEUROLOGICAL DISEASES
  • TABLE 233 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 234 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 235 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: I IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 237 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 238 MIDDLE EAST IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 239 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 240 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 241 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 242 EUROPE IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 243 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 244 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 245 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 246 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 247 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 248 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 249 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 250 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 251 ASIA PACIFIC IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 252 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 253 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 254 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 255 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 256 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 257 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 258 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 259 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 260 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 261 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 262 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 263 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 264 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 266 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 267 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 268 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 269 IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 270 NORTH AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 271 EUROPE: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 273 LATIN AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 274 MIDDLE EAST: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 275 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 276 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 277 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 278 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 279 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 280 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 281 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 282 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 283 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 284 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 285 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 286 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 287 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 288 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 289 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 290 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 291 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 292 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 293 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 295 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 296 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 297 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 298 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 299 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 300 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 301 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 302 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 303 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 304 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 305 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 306 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 307 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 308 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 309 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 310 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 311 US: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET
  • TABLE 312 US: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 313 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 314 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 315 US: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 316 US: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 317 US: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 318 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 319 US: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 320 US: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 321 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 322 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 323 CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 324 CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 325 CANADA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 326 CANADA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 327 CANADA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 328 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 329 CANADA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 330 CANADA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 331 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 332 EUROPE: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET
  • TABLE 333 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 334 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 335 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 336 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 337 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 338 EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 339 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 340 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 341 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 342 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 343 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 344 EUROPE: KEY MACROINDICATORS
  • TABLE 345 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 346 GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 347 GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 348 GERMANY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 349 GERMANY: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 350 GERMANY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 351 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 352 GERMANY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 353 GERMANY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 354 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 355 UK: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 356 UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 357 UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 358 UK: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 359 UK: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 360 UK: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 361 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 362 UK: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 363 UK: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 364 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 365 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 366 FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 367 FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 368 FRANCE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 369 FRANCE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 370 FRANCE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 371 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 372 FRANCE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 373 FRANCE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 374 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 375 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 376 ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 377 ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 378 ITALY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 379 ITALY: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 380 ITALY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 381 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 382 ITALY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 383 ITALY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 384 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 385 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 386 SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 387 SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 388 SPAIN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 389 SPAIN: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 390 SPAIN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 391 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 392 SPAIN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 393 SPAIN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 394 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 395 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 396 REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 397 REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 398 REST OF EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 399 REST OF EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 400 REST OF EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 401 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 402 REST OF EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 403 REST OF EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 404 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 405 ASIA PACIFIC: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET
  • TABLE 406 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 407 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 408 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 409 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 410 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 411 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 412 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 413 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 414 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 415 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 416 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 417 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 418 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 419 CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 420 CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 421 CHINA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 422 CHINA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 423 CHINA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 424 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 425 CHINA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 426 CHINA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 427 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 428 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 429 JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 430 JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 431 JAPAN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 432 JAPAN: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 433 JAPAN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 434 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 435 JAPAN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 436 JAPAN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 437 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 438 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 439 INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 440 INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 441 INDIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 442 INDIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 443 INDIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 444 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 445 INDIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 446 INDIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 447 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 448 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 449 AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 450 AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 451 AUSTRALIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 452 AUSTRALIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 453 AUSTRALIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 454 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 455 AUSTRALIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 456 AUSTRALIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 457 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 458 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 459 SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 460 SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 461 SOUTH KOREA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 462 SOUTH KOREA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 463 SOUTH KOREA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 464 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 465 SOUTH KOREA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 466 SOUTH KOREA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 467 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 468 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 469 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 470 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 471 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 472 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 473 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 474 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 475 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 476 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 477 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 478 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 479 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 480 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 481 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 482 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 483 LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 484 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 485 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 486 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 487 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 488 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 489 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 490 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 491 BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 492 BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 493 BRAZIL: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 494 BRAZIL: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 495 BRAZIL: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 496 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 497 BRAZIL: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 498 BRAZIL: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 499 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 500 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 501 MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 502 MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 503 MEXICO: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 504 MEXICO: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 505 MEXICO: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 506 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 507 MEXICO: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 508 MEXICO: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 509 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 510 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 511 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 512 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 513 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 514 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 515 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 516 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 517 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 518 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 519 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 520 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 521 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 522 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 523 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 524 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 525 MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 526 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 527 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 528 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 529 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 530 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 531 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 532 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 533 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 534 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 535 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 536 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 537 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 538 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 539 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 540 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 541 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 542 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 543 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 544 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 545 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 546 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 547 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 548 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 549 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 550 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 551 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 552 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 553 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 554 UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 555 UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 556 UAE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 557 UAE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 558 UAE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 559 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 560 UAE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 561 UAE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 562 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 563 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 564 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 565 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 566 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 567 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 568 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 569 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 570 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 571 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 572 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 573 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 574 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 575 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 576 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 577 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 578 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 579 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 580 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 581 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 582 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 583 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 584 AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 585 AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
  • TABLE 586 AFRICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 587 AFRICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 588 AFRICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 589 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 590 AFRICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 591 AFRICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 592 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 593 AFRICA: KEY MACROINDICATORS
  • TABLE 594 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET
  • TABLE 595 IMMUNOHISTOCHEMISTRY MARKET: DEGREE OF COMPETITION
  • TABLE 596 IMMUNOHISTOCHEMISTRY MARKET: OFFERING FOOTPRINT
  • TABLE 597 IMMUNOHISTOCHEMISTRY MARKET: APPLICATION FOOTPRINT
  • TABLE 598 IMMUNOHISTOCHEMISTRY MARKET: REGION FOOTPRINT
  • TABLE 599 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 600 IMMUNOHISTOCHEMISTRY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 601 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2024
  • TABLE 602 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2021–JULY 2024
  • TABLE 603 IMMUNOHISTOCHEMISTRY MARKET: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 604 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2024
  • TABLE 605 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 606 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 607 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2024
  • TABLE 608 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–JULY 2024
  • TABLE 609 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 610 DANAHER CORPORATION: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 611 DANAHER CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2024
  • TABLE 612 DANAHER CORPORATION: DEALS, JANUARY 2021–JULY 2024
  • TABLE 613 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 614 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 615 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2024
  • TABLE 616 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–JULY 2024
  • TABLE 617 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 618 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 619 PHC HOLDINGS CORPORATION: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 620 PHC HOLDINGS CORPORATION: DEALS, JANUARY 2021– JULY 2024
  • TABLE 621 PHC HOLDINGS CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2024
  • TABLE 622 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 623 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 624 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 625 MERCK KGAA: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 626 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 627 BIO-RAD LABORATORIES, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 628 BIO-TECHNE: COMPANY OVERVIEW
  • TABLE 629 BIO-TECHNE: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 630 BIO-TECHNE: DEALS, JANUARY 2021– JULY 2024
  • TABLE 631 BIO-TECHNE: EXPANSIONS, JANUARY 2021– JULY 2024
  • TABLE 632 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2021– JULY 2024
  • TABLE 633 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 634 BECTON, DICKINSON AND COMPANY: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 635 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2021– JULY 2024
  • TABLE 636 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 637 TAKARA BIO INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 638 ENZO BIOCHEM INC.: COMPANY OVERVIEW
  • TABLE 639 ENZO BIOCHEM INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 640 ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 641 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW
  • TABLE 642 SINO BIOLOGICAL, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 643 SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 644 SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW
  • TABLE 645 SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 646 SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES, JANUARY 2021–JULY 2024
  • TABLE 647 SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2021–JULY 2024
  • TABLE 648 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW
  • TABLE 649 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 650 CELL SIGNALING TECHNOLOGY, INC.: DEALS, JANUARY 2021–JULY 2024
  • TABLE 651 BIO SB: COMPANY OVERVIEW
  • TABLE 652 BIO SB: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 653 BIO SB: PRODUCT LAUNCHES, JANUARY 2021–JULY 2024
  • TABLE 654 MILTENYI BIOTEC: COMPANY OVERVIEW
  • TABLE 655 MILTENYI BIOTEC: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 656 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 657 ORIGENE TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 658 EAGLEBIO: COMPANY OVERVIEW
  • TABLE 659 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW
  • TABLE 660 ELABSCIENCE BIONOVATION INC.: COMPANY OVERVIEW
  • TABLE 661 BIOGENEX: COMPANY OVERVIEW
  • TABLE 662 DIAGNOSTIC BIOSYSTEMS INC.: COMPANY OVERVIEW
  • TABLE 663 HISTO-LINE LABORATORIES: COMPANY OVERVIEW
  • TABLE 664 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW
  • TABLE 665 CANDOR BIOSCIENCE GMBH: COMPANY OVERVIEW
  • TABLE 666 GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 IMMUNOHISTOCHEMISTRY MARKET: SEGMENTS & REGIONS COVERED
  • FIGURE 2 IMMUNOHISTOCHEMISTRY MARKET: YEARS CONSIDERED
  • FIGURE 3 IMMUNOHISTOCHEMISTRY MARKET: RESEARCH DESIGN
  • FIGURE 4 IMMUNOHISTOCHEMISTRY MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2023)
  • FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 7 ILLUSTRATIVE EXAMPLE OF F. HOFFMAN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET: CAGR PROJECTION, 2024–2029
  • FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL SNAPSHOT
  • FIGURE 17 GROWING PREVALENCE OF CANCER AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET
  • FIGURE 18 US AND DIAGNOSTIC APPLICATIONS DOMINATED NORTH AMERICAN MARKET IN 2023
  • FIGURE 19 ANTIBODIES TO DOMINATE IMMUNOHISTOCHEMISTRY MARKET IN 2029
  • FIGURE 20 HOSPITALS AND DIAGNOSTIC LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 22 IMMUNOHISTOCHEMISTRY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 RATE OF CANCER INCIDENCE, BY REGION AND CANCER TYPE (2022)
  • FIGURE 24 SHARE OF PERSONALIZED MEDICINES APPROVED BY FDA (2015–2023)
  • FIGURE 25 IMMUNOHISTOCHEMISTRY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • FIGURE 26 AVERAGE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023
  • FIGURE 27 AVERAGE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY CONSUMABLES, 2021–2023
  • FIGURE 28 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024
  • FIGURE 29 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
  • FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING PHASE
  • FIGURE 31 IMMUNOHISTOCHEMISTRY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 32 IMMUNOHISTOCHEMISTRY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 33 IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IMMUNOHISTOCHEMISTRY PRODUCTS
  • FIGURE 35 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 36 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 37 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 38 EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 39 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 40 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 41 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 42 IMMUNOHISTOCHEMISTRY MARKET: IMPACT OF AI/GEN AI
  • FIGURE 43 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT (2023)
  • FIGURE 44 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT (2023)
  • FIGURE 45 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET (2021–2023)
  • FIGURE 46 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET (2023)
  • FIGURE 47 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 48 IMMUNOHISTOCHEMISTRY MARKET: COMPANY FOOTPRINT
  • FIGURE 49 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 50 PRICE-TO-EARNINGS(P/E) RATIO OF KEY VENDORS
  • FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 52 IMMUNOHISTOCHEMISTRY MARKET: BRAND/COMPARISON
  • FIGURE 53 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 54 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 56 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 57 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 58 MERCK KGAA: COMPANY SNAPSHOT (2023)
  • FIGURE 59 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 60 BIO-TECHNE: COMPANY SNAPSHOT (2023)
  • FIGURE 61 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 62 TAKARA BIO INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 63 ENZO BIOCHEM INC.: COMPANY SNAPSHOT (2023)

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global Immunohistochemistry market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources [such as the World Bank, World Health Organization (WHO), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Centre for Biotechnology Information (NCBI), Therapeutic Goods Administration (TGA), and Centers for Disease Control and Prevention (CDC)]; sites like ClinicalTrials.gov, fiercebiotech, and annual reports; SEC filings; press releases; investor presentations; journals; expert interviews; MarketsandMarkets analysis; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global immunohistochemistry market, which was validated through primary research.

Primary Research

After acquiring basic knowledge about the global immunohistochemistry market scenario through secondary research, extensive primary research was conducted. Several primary interviews were conducted with market experts from both the supply and the demand side participants (such as clinical diagnostic laboratories, hospitals, etc. ) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews. The following is a breakdown of the primary respondents:

The following is a breakdown of the primary respondents:

Immunohistochemistry  Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the immunohistochemistry market was estimated through different approaches. A detailed market estimation approach was followed to estimate and validate the global market value and other dependent submarkets, as mentioned below. Both top-down and bottom-up approaches were used to estimate and validate the total size of the immunohistochemistry (IHC) market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the immunohistochemistry business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Approach 1: Company Revenue Analysis (Bottom-Up Approach)

  • Revenues for individual companies were gathered from public sources and databases.
  • The immunohistochemistry (IHC) business share of leading players was gathered from secondary sources to the extent available. In certain cases, the share of IHC product businesses was ascertained through a detailed analysis of various parameters, including product portfolios and market positioning.
  • Individual share or revenue estimates were validated through expert interviews.

Immunohistochemistry  Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Approach 2: Top-Down Approach

Immunohistochemistry  Market Size, and Share

The segmental assessment was conducted using the following approaches:

  • Approach for Offerings: Revenue contributions/splits of different segments to the total revenues of leading market players (wherever available) and respective growth trends were derived through extensive primary and secondary analysis.
  • Approach for Application: Splits for segments were derived by studying the product portfolios offered for various applications. This information was validated through primary interviews.
  • Approach for End User: Splits for segments were derived by analyzing the views on the adoption of various products obtained from primary and secondary data for end users considered in the study.
  • Approach for Region: The regional assessment was conducted by studying the regional revenue contributions/splits of leading market players (wherever available) and their respective growth trends.

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Market Definition:

Immunohistochemistry (IHC) is a laboratory technique that uses antibodies to test detect and visualize specific proteins or antigens within tissue sections utilizing a combination of immunological, anatomical, and biochemical techniques. This method involves the binding of antibodies that are conjugated to a detectable marker, such as an enzyme or fluorescent dye, to the target tissues. These antibodies bind to their target antigens, allowing for the localization and quantification of the proteins within the tissue. There are multiple approaches used in immunohistochemistry for drug testing and the diagnosis of chronic diseases, such as cancer, infectious diseases, cardiovascular diseases, diabetes, and autoimmune diseases.

Key Stakeholders

  • Manufacturers and Distributors of Immunohistochemistry Products
  • Third-party Suppliers of Immunohistochemistry Products
  • Contract Research Organizations
  • Market Research and Consulting Firms
  • R&D Centers and Institutes
  • Hospitals and Clinics
  • Academic Institutions
  • Diagnostic Laboratories

Report Objectives

  • To define, describe, and forecast the Immunohistochemistry market by product, application, end user, and region.
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges).
  • To strategically analyze the micro markets with respect to individual growth trends, prospects, and contributions to the overall market.
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, the Middle East and Africa.
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To track and analyze competitive developments such as acquisitions, collaborations, and product launches in the Immunohistochemistry market.
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5), inclusive of:
    • Business Overview
    • Financial Information
    • Product Portfolio
    • Developments (Last Three Years)

Previous Versions of this Report

Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics (Cancer, Infectious, Autoimmune Diseases), Research, Forensic), End Users (Diagnostic laboratories, Research Institute) - Global Forecast to 2028

Report Code BT 4780
Published in Jun, 2023, By MarketsandMarkets™

Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics (Cancer, Infectious, Autoimmune Diseases), Research, Forensic), End user (Hospitals, Diangostic labs, Academia) - Global Forecast to 2026

Report Code BT 4780
Published in Nov, 2021, By MarketsandMarkets™

Immunohistochemistry/IHC Market by Product (Antibodies, Reagents (Chromogenic Substrates), Kits), Application (Diagnostics (Cancer, Infectious), Research, Forensic), End User (Hospitals, Diagnostic Laboratories, Academic) - Global Forecast to 2025

Report Code BT 4780
Published in Jul, 2020, By MarketsandMarkets™

Immunohistochemistry/IHC Market by Product (Antibodies, Reagents (Chromogenic Substrates), Kits), Application (Diagnostics (Cancer, Infectious), Research, Forensic), End User (Hospitals, Diagnostic Laboratories, Academic) - Global Forecast to 2025

Report Code BT 4780
Published in Nov, 2016, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Immunohistochemistry Market

Henry

Oct, 2022

What are the growth estimates for the Global Immunohistochemistry Market by 2030?.

Thomas

Oct, 2022

Which geography holds the major share of the Global Immunohistochemistry Market?.

Freddie

Oct, 2022

Want to know more about growth strategies adopted by key players of the global Immunohistochemistry Market..

DMCA.com Protection Status